Keyphrases
Denmark
100%
Hepatitis C Virus
88%
Chronic Hepatitis C
70%
People Living with HIV (PLHIV)
52%
National Cohort Study
39%
Hepatitis C Virus Infection
37%
Hepatitis C
35%
Hepatitis C Virus Genotypes
33%
Hepatocellular Carcinoma
31%
Confidence Interval
30%
COVID-19
30%
Hepatitis B Virus
26%
Cirrhosis
26%
Sustained Virological Response
23%
AIDS/HIV
21%
Hepatitis C Virus RNA
20%
Chronic Hepatitis B
20%
Human Immunodeficiency Virus Type 1 (HIV-1)
20%
Antiretroviral Therapy
17%
Infected Patients
16%
Genotype 1
16%
Direct-acting Antivirals
15%
Risk Factors
15%
Ribavirin
15%
Chronic Hepatitis C Virus Infection
14%
Genotype
14%
Europe
14%
Liver Stiffness
14%
Nordic Countries
13%
Copenhagen
13%
Virus
12%
During Pregnancy
12%
HIV Patients
12%
High-income Setting
12%
Chronic Hepatitis B Virus Infection
11%
Incidence Rate
11%
Genotype 3
11%
Hepatitis C Virus Genotype 3
11%
Liver
11%
Living with
11%
Infectious Diseases
11%
Hepatitis B
10%
HIV-exposed
10%
Liver Fibrosis
10%
Pregnant Women Living with HIV
10%
Disease Burden
10%
Viral Hepatitis
10%
Transient Elastography
10%
Daclatasvir
9%
Neutralizing Antibodies
9%
Medicine and Dentistry
Human Immunodeficiency Virus
89%
Hepatitis C Virus
59%
Chronic Hepatitis C
59%
Infection
39%
Hepatitis C
37%
Prevalence
37%
Cohort Analysis
30%
Chronic Hepatitis B
29%
Hepatitis B Virus
27%
Liver Cirrhosis
25%
Hepatocellular Carcinoma
22%
Antivirus Agent
18%
Fibrosis
17%
COVID-19
14%
Hepatitis B
13%
Population
12%
Systematic Review
12%
Antiviral Therapy
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Liver Disease
11%
Childbirth
11%
Ribavirin
10%
Transient Elastography
10%
Symptom
9%
Birth Outcomes
9%
Liver Fibrosis
8%
Antiretroviral Therapy
8%
Disease Burden
8%
Odds Ratio
7%
Cross Sectional Study
7%
Gene Linkage
7%
Mixed Infection
6%
Coronavirinae
6%
Infant Feeding
6%
Ritonavir
6%
Diagnosis
6%
Hepatitis Virus
6%
Randomized Controlled Trial
6%
Adverse Event
6%
Doravirine
6%
Darunavir
6%
Hepatitis A
6%
Viral Clearance
5%
Virus RNA
5%
Hepatitis C Virus Genotype 3
5%
Virus Infection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
66%
Hepatitis C Virus
59%
Infection
50%
Prevalence
50%
HIV
45%
Hepatitis C
35%
Chronic Hepatitis B
30%
Cohort Study
27%
Antivirus Agent
27%
Liver Cirrhosis
25%
Hepatitis B Virus
20%
Ribavirin
19%
Fibrosis
17%
Disease
16%
Liver Cell Carcinoma
13%
Liver Disease
13%
Liver Fibrosis
11%
Hepatitis C Virus Genotype 3
10%
Cross-Sectional Study
10%
Virus RNA
9%
Peginterferon
9%
Mixed Infection
9%
Daclatasvir
9%
Bacteremia
9%
Neutralizing Antibody
9%
Elimination
9%
Hepatitis B
8%
Biological Marker
8%
Placebo
7%
Lamivudine
6%
Decompensated Liver Cirrhosis
6%
Hepatitis C Virus Genotype 1
6%
Virus Hepatitis
6%
Mortality Rate
6%
Ritonavir
6%
Vaccination Policy
6%
Antiviral Therapy
6%
Doravirine
6%
Mannose Receptor
6%
Chronic Obstructive Lung Disease
6%
Darunavir
6%
Coronary Artery Disease
6%
Adverse Event
5%
C Reactive Protein
5%
Sofosbuvir
5%
Virus Infection
5%
